Beyond Trial and Error: A Systematic Development of Liposomes Targeting Primary Macrophages by Weber, Florian et al.
Beyond Trial and Error: A Systematic Development of
Liposomes Targeting Primary Macrophages
Florian Weber, Daniela C. Ivan, Steven T. Proulx, Giuseppe Locatelli, Simone Aleandri,*
and Paola Luciani*
1. Introduction
Monocytes/macrophages are phagocytic innate immune cells
populating every organ of the body and playing a pivotal role
in regulating tissue homeostasis, inflam-
mation, and antitumor immunity in a
microenvironment-dependent manner.[1]
Their distinct transcriptional plasticity
allows these cells to integrate local and sys-
temic cues and exert a continuous spec-
trum of functions, ranging from tissue
damage to wound healing. Thanks to the
ability of monocytes to infiltrate inflamed
tissues and differentiate into monocyte-
derived macrophages (MdMs), monocytes
have also been exploited as a drug delivery
target in a broad range of pathologies span-
ning from cancer to Alzheimer’s and
Parkinson’s disease.[2] Due to their surface
expression of pattern recognition and scav-
enger receptors (SRs), macrophages selec-
tively take up pathogens and cellular
debris,[3] a property that can be utilized
for cell-specific drug targeting. It was suc-
cessfully demonstrated that the decoration
of the surface of nanocarriers with ligands
such as antibodies, mono- and polysacchar-
ides, and lectins resulted in an increased
macrophage uptake.[4] Remarkable preclin-
ical success has been obtained using
liposomes,[5–8] which exhibit low toxicity and whose lipid
composition can be modified to control physical and chemical
properties such as fluidity and surface charge. Specific macro-
phage targeting is obtained by fine tuning liposome characteris-
tics such as lipid composition,[9] size, and surface charge.[4,10]
Engineered vesicles with negatively charged phospholipids
(NPLs), such as phosphatidylserine (PS), have received growing
interest for their ability to be engulfed by macrophages through
SR-mediated endocytosis.[4] Under physiological conditions, PS
is preferentially located on the inner leaflet of eukaryotic plasma
membrane and in endocytic membranes, whereas phosphocho-
line (PC) resides more commonly in the outer leaflet. However,
this asymmetrical arrangement is altered when cells undergo
apoptosis when PS is exposed on the outer leaflet of the
membrane, a phenomenon that also occurs during non-
apoptotic cell death.[11] The exposure of the PS domain on the
cell surface via the action of scramblases provokes a so-called
eat-me-signal responsible for the initiation of intracellular
signaling cascades, cytoskeletal rearrangement, and debris
engulfment by macrophages.[12,13] PS is one of the best
characterized membrane-anchored eat-me signals and its recog-
nition is a stereo-specific process: only L-phosphoserine is
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Monocytes/macrophages are phagocytic innate immune cells playing a pivotal
role in tissue homeostasis, inflammation, and antitumor immunity in a
microenvironment-dependent manner. By expressing pattern recognition and
scavenger receptors on their surface, macrophages selectively take up pathogens,
cellular debris, and often—undesirably—drug delivery systems. On the other
hand, the propensity of phagocytic cells to internalize particulate drug carriers is
used to load them with a cargo of choice, turning the monocytes/macrophages
into a diagnostic or therapeutic Trojan horse. Identifying the ideal physico-
chemical properties of particulate carriers such as liposomes to achieve the most
efficient macrophage-mediated drug delivery has been object of extensive
research in the past, but the studies reported so far rely solely on trial-and-error
approaches. Herein, a design of experiment (DoE) strategy to identify the optimal
liposomal formulation is proposed, fully characterized in terms of size, surface
charge, and membrane fluidity, to maximize macrophage targeting. The findings
are validated using mouse bone marrow-derived macrophages, a primary
preparation modeling in vivo monocyte-derived macrophages, thus confirming
the robustness and versatility of the systematic and iterative approach and
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recognized and engulfed either as a mere lipid or in combination
with other soluble proteins.[14]
Furthermore, phosphatidylglycerol (PG), as a major compo-
nent of Gram-negative bacterial cell membranes, represents
an essential ligand for different phagocytes.[15] PG-based lipo-
somes have shown anti-inflammatory activities in a recent
in vitro study with decreased TNFα-production of lipopolysaccha-
ride-stimulated mouse peritoneal macrophages.[16] Other head-
groups, such as phosphatic acid (PA), with a crucial role in
vesicle trafficking and endocytosis,[17] have been shown to be
taken up by alveolar macrophages upon administration of
PA-based liposomal aerosols in vivo. Finally, given the high
expression of mannose receptors (MRs) in most tissue-resident
macrophages and certain MdMs, mannosylated liposomes have
also demonstrated efficient macrophage targeting, both in vitro
and in vivo.[18,19]
Despite the manifold literature available addressing the corre-
lation between macrophage uptake and physicochemical proper-
ties of carrier formulation, trial-and-error approaches to target
macrophages are still the predominant modality in small-scale
production. In academia and in laboratory-scale product develop-
ment, the proclivity to test as many formulations as possible to
ultimately identify a suitable candidate for further evaluation
(Quality by Testing) is indeed a deeply-rooted—albeit often
inefficient—philosophy.[9] In contrast, the risk-minimizing phar-
maceutical Quality by Design (QbD) approach proposes to evalu-
ate a formulation and the corresponding manufacturing process
through its key material attributes and process parameters and,
aided by the gained information and a sound risk assessment,
can improve the understanding of the formulation and the process
over the product lifecycle.[20] A fundamental aspect of QbD is the
use of a design of experiment (DoE) strategy to screen the range of
formulation parameters that have been demonstrated to provide
assurance of quality. The DoE approach uses a rational and statis-
tically validated method that designs the number of experiments
depending on the parameters to be optimized while providing
insights into the decision-making process, as recommended by
the FDA (FDA 2007; ICH Q8 guidelines). The implementation
of a DoE approach has been increasingly used to develop formu-
lations for a wide range of dosage forms including liposomes,
micelles, dendrimers, polymeric nanoparticles, and micropar-
ticles.[21–24] Recently, a DoE approach was used to estimate the
macrophage sequestration of liposomes functionalized with differ-
ent poly(ethylene) glycols (PEGs) in zebrafish embryos.[25]
Different from what is proposed in the majority of the available
literature, we conceived the present study relying on a systematic
approach that would enable the examination of several variables at
the same time and the correlation of the liposomal properties to
macrophage targeting. Our driving hypothesis was that by select-
ing and combining different lipids, the features of the derived
nanomaterial by design would be affected, thereby providing
control over liposome uptake. Accordingly, four independent
DoEs, where the neutral lipids (1,2-dioleoyl-sn-glycero-3-
phosphocholine [DOPC], 1-palmitoyl-2-oleoyl-glycero-3-phospho-
choline [POPC], 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
[DPPC], and DOPCþ 1,2-distearoyl-sn-glycero-3-phosphocholine
[DSPC] 50/50 mixture) were formulated together with negatively
charged lipids (1,2-dioleoyl-sn-glycero-3-phospho-L-serine [DOPS],
1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-serine
[POPS], 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (DPPS),
and L-alpha-PS from brain [Brain PS], respectively) and cholesterol
(Chol), were carried out. Once the optimal lipid proportion and
composition to maximize uptake were found, the types of NPLs
and the liposome size were varied stepwise as well.
In initial screenings, the RAW264.7 mouse cell line was used
as a widely acknowledged monocyte/macrophage model typically
in in vitro liposome phagocytosis assays. However, RAW264.7
cells are an immortalized model that does not fully resemble
the physiological phagocytosis observed in ex vivo macro-
phages.[26] As a systematic comparison between liposome uptake
by RAW264.7 cells and by primary macrophages is missing to
date, we aimed at further confirmation of our findings using
mouse bone marrow-derived macrophages (BMDMs), a primary
preparation often used to model the properties of
tissue-resident macrophages or inflammatory MdMs depending
on the specific experimental scenario.[27] Our systematic
approach guided us to the identification of a liposomal formula-
tion specifically, efficiently taken up by RAW264.7 cells. The opti-
mal candidate from QbD screening also exhibited similar uptake
by BMDMs, thus validating the robustness and versatility of our
iterative procedure in the formulation optimization for cell tar-
geting and suggesting the translational potential of a DoE design
for subsequent in vivo studies.
2. Results and Discussion
Fine tuning liposome properties such as size, surface, and
bilayer rigidity is crucial to determine if and how macrophages
can internalize a therapeutic cargo.[28] The proposed investiga-
tion is built on a DoE approach which allows us to simulta-
neously alter either the lipid composition or the lipid
proportions and observe how these changes affect the chosen
outcome, in our case macrophage uptake. Four independent
DoEs were conducted, in which the neutral lipids were formu-
lated together with Chol and negatively charged PS, as the inclu-
sion of PS in formulations represents a reference procedure
when aiming for phagocytosis in therapeutic formulations.[29–34]
Once the optimal proportion between the components (neutral,
Chol, and PS) was found and the best candidate between the four
DoEs selected, the headgroup of the NPL and the size of liposomes
were varied stepwise and their uptake evaluated using the
RAW264.7 cell line and primary BMDMs.
2.1. Varying the Liposome Formulation: Effect of the Lipid
Chain and Cholesterol
To ensure that the obtained differences in uptake were not
dependent on formulation variability, all produced liposomes
were first fully characterized in terms of size, zeta potential,
and molar percentages of each lipid in the formulations. As
expected, the zeta potential and the particle size were similar
for each set of experiments between the liposomes containing
the same NPL, whereas the particle charge decreased as the per-
centage of NPL increased (Figure 1A,B). The molar percentages
of each lipid in the liposomal formulations after preparation were
not divergent from the theoretical values (see Figure S7,
Supporting Information) and all the produced formulations were
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stable over 1month (See Figure S8 and S9, Supporting
Information).
To correlate the characteristics of the lipid chain with the mac-
rophage uptake, the anisotropy (r) of the liposomes was deter-
mined as a measure of the membrane motional fluidity.
A shorter chain length and the introduction of cis double
bonds in the acyl chains are reported to be responsible for a
decreased phase transition temperature (Tm), which in turn
causes reduced rigidity and lower anisotropy.[35] Interestingly,
DOPC-based liposomes, containing either different amounts
of PS or Chol (DOPX series) with the lowest anisotropy value
(Figure 1C), showed the highest uptake by RAW264.7 cells with
respect to the other lipids at 37 C (Figure 2A), whereas the
DOPC/DSPC- and the POPC-based liposomes (Brain PX and
POPX series, respectively) with intermediate anisotropy values
showed the second- and third-highest uptake (3.3-fold and 4.8-
fold lower than DOPC, respectively).
DPPC liposomes (DPPX series), having a Tm (41 C) higher
than physiological temperature, are the most rigid, and showed
the poorest uptake by RAW264.7 cells (6.4-fold lower than
DOPC). Although these results suggest that the fluidity of the
acyl chain contributes to particle uptake, a direct correlation
between those two parameters was not possible: despite the fact
that POPC liposomes have a lower anisotropy than the DOPC/
DSPC mixture, the latter formulation was taken up to a higher
extent. POPC/POPS-based liposomes which modulate various
cellular signaling pathways have been already used to reprogram
macrophages,[36] and POPC is responsible for the activation of
alveolar macrophages and regulating their production of cyto-
kines.[37] However, the liposomal effect was attributed mainly
to the presence of PS, whereas a comparison with other PC-based
liposomes and the lipid chain contribution on the uptake has so
far been completely missing. Herein, the superior uptake of
DOPC/DSPC mixture (Brain PX series) may be attributed to
the fully unsaturated DOPC domain in the formulations, which
is the predominant lipid determining the interaction with the cel-
lular membrane, resulting in elevated endocytosis.[38–42]
Therefore, it became apparent that the lipid chain fluidity of
the formulation should not be the only parameter evaluated
and that other variables should be considered when correlating
the liposomal features with their uptake. The incorporation of
Chol in the liposomal membrane is widely used to modulate
membrane fluidity and therefore vesicle stability.[37–39]
However, the influence of Chol on liposome uptake is elusive
and the reported publications are limited and inconsis-
tent.[10,41,43-50] However in some studies the inclusion of Chol
was observed to enhance immune responses, other investiga-
tions have demonstrated that liposomes containing Chol showed
decreased adjuvant effects. For example, Jiskoot and coworkers
demonstrated a significantly elevated uptake by dendritic cells
after the incubation with Chol-containing liposomes compared
with Chol-free vesicles.[51] In addition, successful phagocytic cell
Figure 1. A) Size and PDI, B) zeta potential, and C) anisotropy, for the DOPX (DOPC-based liposomes containing different amount of PS and Chol; green
bars), POPX (POPC-based liposomes containing different amount of PS and Chol; blue bars), DPPX (DPPC-based liposomes containing different amount
of PS and Chol; brown bars), and Brain PX series (DOPC/DSPC-based liposomes containing different amount of PS and Chol; red bars). Data are
represented as mean SD (n¼ 3).
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uptake using PS-liposomes with 32mol% Chol has been shown,
suggesting the importance of this excipient in macrophage-tar-
geting applications.[31] Conversely, it has been reported that
the inclusion of Chol at a high percentage (>50%), and thus aug-
mented particle rigidity, resulted in a decreased uptake by
macrophages.[48]
As shown in Figure 2, Chol has a remarkable impact on the
formulation uptake. The effect is especially evident in the evalu-
ation of the series containing the same amount of PS (30mol %)
and different percentages of Chol: the Chol-free formulation
results in a RAW264.7 uptake 2- and 4-fold lower than the lip-
osomes containing 15 and 30mol% Chol, respectively. It has
been described that macrophages take up Chol-rich remnants
of lipoproteins through low-density lipoprotein receptors, SRs
of class B type I, and fluid-phase pinocytosis.[49,50,52]
Therefore, liposomes with a high cholesterol content, having
adsorbed opsonizing proteins on their surface, appear to mimic
natural chylomicrons and can thus be actively taken up by
macrophages.
Nevertheless it has to be noted that in the case of PEGylated
liposomes, of which the Chol-enriched surface is shielded by
PEG chains, their opsonization is lower with respect to the
non-PEGylated ones.[14] However, it has been reported that
although PEGylated liposomes are barely taken up by macro-
phages at the steady state, PEGylated liposomes display a prefer-
ential affinity for and a higher uptake from activated
macrophages in inflammatory diseases such as arthritis.[53]
In summary, the results of our DoE-led experiments, in agree-
ment with the findings from other groups, strongly support the
hypothesis that a high Chol content (40 5mol%) markedly
contributes to an increased uptake of non-PEGylated liposomes
by macrophages.
2.2. NPL Content
As already proposed by other authors, the statistical evaluation
of our data by response optimization (Table S10–S13,
Supporting Information) displays that the liposomal uptake
by macrophages is a PS concentration-dependent phenome-
non, and it reaches its maximum when the PS content is
25 5 mol%.[29,31,33] Until now, several receptors involved
in PS-mediated uptake have been described including BAI1,
Tim-1, Tim-2, Tim-4, Stabilin-2, CD300, and TREM2.[54]
Ouyang et al. described T-cell immunoglobin mucin 4
(Tim-4) as a possible candidate for PS recognition.[55] This
receptor is normally expressed on the surface of macrophages
and mediates binding to surrounding apoptotic bodies. After
binding to PS, Tim-4 is also directly involved in the engulf-
ment of particles. Moreover, a second possible pathway for
the uptake of negatively charged liposomes is their aforemen-
tioned affinity to opsonizing proteins such as complement
components or immunoglobulins in the presence of serum.
Several groups have identified that these proteins can increase
the interactions between the negatively charged liposomes and
Figure 2. A) Geometric mean of the fluorescence intensity of RAW264.7 cells after incubation with formulations composed of DOPX (green bars), POPX
(blue bars), DPPX (brown bars), and Brain PX series (red bars). PS: The corresponding phosphatidylserine. Data are represented as mean SD (n¼ 3).
B) Representative histograms of the formulations with the highest and the lowest uptake for each set of experiments in comparison with the blank
(untreated cells).
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macrophages.[56–60] However, due to their variety, a compre-
hensive explanation of PS binding still remains unclear.
2.3. Statistical Evaluation and Model Analysis
The contour plots (Figure 3) summarize how the response (i.e.,
the liposome uptake, expressed as geometric mean fluorescence
intensity values obtained from flow cytometry experiments)
relates to lipid proportion. The graph provides a 2D view in
which all points that have the same response are linked to pro-
duce contour lines of constant responses. Colored contour bands
(which represent ranges of the response values) get darker if the
uptake increases. To maximize this outcome, we had to choose
the proportions for the components in the bottom center of the
design space, where the ratings (i.e., the uptake) are the highest.
It is also worth noting that, for all models, the association
between the response and two-way interaction terms such as
neutral lipids versus NPL or NPL versus Chol is statistically sig-
nificant (Tables S2, S4, S6, and S8, Supporting Information). The
response therefore is dependent on both terms and it increases
as the neutral lipid decreases, whereas the NPL and Chol amount
are increased at the same time, as visible from the contour plots.
On the other hand, the association between the response and
two-way interaction terms such as neutral lipids versus Chol
is not statistically significant, meaning that the uptake is not
affected by the interaction between Chol and neutral lipids.
Moreover, the response optimization (Tables S10–S13,
Supporting Information) was used to identify the best lipid pro-
portion able to maximize the macrophage uptake. Overall, our
findings suggest that liposomes mainly composed of DOPC,
independent of the proportions between the lipid components,
result in the higher uptake by RAW264.7 cells with respect to
the POPC-, DOPC/DPPS-, and the DPPC-based liposomes.
The maximum uptake can be achieved with the formulation con-
taining 40% of DOPC, 22% of DOPS, and 38% of Chol. The
results are in line with those reported in literature, where
DOPS/Chol-liposomes imply a 5.3-fold increase in uptake com-
pared with neutral liposomes in a macrophage cell model.[9]
Moreover, these predicted results estimated by the analysis of
mixture design are in agreement with those evaluated experi-
mentally (See Table S10–S13, Supporting Information).
Therefore, the proposed model is an easy approach for optimi-
zation of lipid mixtures of liposomes and it enables theoretical
understanding of optimal liposome formulation.
2.4. Influence of the Headgroup
Starting from the best formulation obtained from the DoE anal-
ysis (40% of DOPC, 22% of DOPS, and 38% of Chol), the PS
headgroup was replaced with glycerol (PG), PA, or mannose
(Man) headgroups to assess if and how different surface moieties
would influence the liposome/cell interactions. As earlier, all the
vesicles were fully characterized (see Figure 4). They had similar
fluorescent intensity and exhibited no differences in cell viability
Figure 3. Response contour plot for the A–D) DOPX, POPX, DPPX, and Brain PX series (respectively). The colored contour bands show ranges of
different geometric mean fluorescence intensity values obtained from flow cytometry experiments (n¼ 3).
www.advancedsciencenews.com www.advnanobiomedres.com
Adv. NanoBiomed Res. 2021, 1, 2000098 2000098 (5 of 12) © 2021 The Authors. Advanced NanoBiomed Research published by Wiley-VCH GmbH
after incubation (See Figure S10 and S11, Supporting
Information, respectively). Moreover, to correlate the uptake with
the different NPLs used and ascertain that the difference in
uptake values was only gained by the different headgroups, a
comprehensive control with fully saturated formulations having
the same chain length (DSPX, C18) was used. As shown in
Figure 4, the liposomes were fully characterized in terms of lipid
composition, surface charge, size, anisotropy, and cellular
uptake. The differences in particle size and lipid content for
all formulations were negligible, whereas the zeta potential of
Man based-liposomes showed a less negative voltage
(≤32mV) due to the electrostatic shielding of the intramolec-
ular PA induced by the mannose linked to triethyleneglycol,
which is in agreement with what has been reported.[61]
As expected, all unsaturated formulations were characterized
by low anisotropy and therefore by high membrane fluidity with
respect to their saturated counterparts.[62] The minor difference
in anisotropy of DOMan and DSMan compared with the other
associated unsaturated or saturated formulations could be
explained by the presence of a mannosylated lipid in the formu-
lation, where a mannose polar headgroup is linked via PEGylated
triazole with a dipalmitoyl chain. For the case of PA- and PG-
based liposomes, the unsaturated formulations showed a supe-
rior uptake with respect to their saturated counterparts, which is
in line with the results described earlier. An exception is given by
theMan based-vesicles, whose saturated, thus more rigid, formu-
lation was preferably taken up. A possible explanation could be
found in the natural function of the MR (MR/CD206).[63] MR is
mostly responsible for binding and aiding the phagocytosis of
mannose-linked microorganisms,[64] with the majority of the nat-
ural receptor substrate mainly located on the surface of bacterial
cell walls characterized by a higher stiffness compared with
mammalian cellular membranes.[65]
As shown in Figure 4E, even though the PS-based liposomes
represent one of the most used formulations to target macro-
phages,[5,9,10] our results revealed that other headgroups,
namely PA, PG, and Man, could lead to a higher macrophage
uptake.
In agreement with our findings, Slütter and coworkers dem-
onstrated that PG-containing liposomes mediated an increased
antigen-specific immune cell response with respect to
PS-containing liposomes.[66] Moreover, PS-liposomes are mainly
dependent on the SR, whereas PG-liposomes have at least one
additional mechanism of uptake such as a Toll-like receptor 4
(TLR4)-dependent binding.[67] Another explanation for the
higher potency of PG-liposomes could be attributed to their
increased affinity to the complement component 1q (C1q)
compared with PS-liposomes. Furthermore, an opsonizing
protein-independent pathway was observed after detecting an
uptake of PG-liposomes in serum-free conditions.[68]
Unfortunately, no satisfying data describing a potential uptake
mechanism by macrophages are available for PA-containing lip-
osomes. Yanasarn et al. demonstrated that DOPA-liposomes
exhibited increased uptake with respect to pure DOPC liposomes
in vitro and upregulated a specific immune response in vivo in
the same manner as DOPS.[68] Furthermore, PA increases the
expression of major histocompatibility complex II (MHC II), a
molecule expressed on the surface of phagocytes responsible
for initiating antigen-specific immune responses.[68]
PA-liposomes are negatively charged in physiological pH and
are therefore characterized by strong interactions with
opsonizing proteins in a similar manner as PS liposomes.
Figure 4. A) Size, B) anisotropy, C) zeta potential, D) UHPLC-CAD lipid quantification, and E) uptake into RAW264.7 cells for the different headgroup
formulations. Data are represented as mean SD (n¼ 3).
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The combination of a protein-corona-driven uptake due to the
interaction with PA on the outer surface can additionally contrib-
ute to an elevated engulfment rate and immune response
initiation.
DSMan liposomes exploit the MR expressed on the macro-
phage’s surface (vide supra) and exhibit superior uptake with
respect to plain liposomes.[61] Despite being a promising candi-
date, the limited availability of mannosylated lipids on the market
led us to the decision to exclude DSMan from further experi-
ments. Our decision was further supported by the absence of
a commercial unsaturated lipid functionalized with Man, a short-
coming that prevented us from establishing a direct correlation
with other DOPC based-formulations.
The influence of different negatively charged headgroups on
the uptake by macrophages is a controversial topic and the avail-
ability of related data is limited and has not been generated in a
systematic fashion. To the best of our knowledge, only the
ability of both PS- and PG-enriched liposomes to act as anti-
inflammatory agents has been investigated,[69] whereas no direct
comparison between these phospholipid headgroups has been
performed so far.
After examining the formulation, resulting in highest macro-
phage internalization, an additional test to investigate the lipo-
somal uptake in a nonmacrophage cell line was conducted
with the aim of evaluating the specificity of our formulation.
The human embryonic kidney 293 cell line (HEK293) was cho-
sen as a model for nonphagocytic cells without engulfment activ-
ity under normal conditions[70] and used as negative control.
After incubation with DOPC, DOPS, and DOPG liposomes,
all particles were equally internalized (see Figure S12,
Supporting Information), indicating the remarkable specificity
of PG and PS liposome toward macrophages.
2.5. Influence of the Particle Size
Another important and controversial parameter is the influence
of the particle size on the uptake by macrophages.[10,71] While it
has been reported that mannose-[72,73] and PS-based lipo-
somes[74] showed augmented uptake with increased size, other
studies suggested an increased opsonization into macrophages
for small negatively charged particles with 100 nm diame-
ter.[38,71,75] Perrie’s group elucidated that positively charged lip-
osomes showed comparable uptake in phagocytes regardless of
particle size (200 nm–2 μm) in vitro.[76] The optimal size seems
to be dependent on the charge (and composition) of the lipo-
some, the cell line, and the targeted receptor mediating the
uptake. In our set of experiments, we produced DOPA,
DOPG, and DOPS liposomes of different sizes, as shown in
Figure 5A. The differences in anisotropy, surface charge, and
composition between the particles were negligible (Figure 5B–D),
as well as the fluorescence intensity and the viability of the par-
ticles after incubation (See Figure S13 and S14, Supporting
Information), thus confirming that the prepared liposomes dif-
fered essentially only in size. As far as the uptake was concerned,
a very clear pattern could be observed, showing that the uptake
was inversely proportional to liposome size. The best outcome
was detected for 100 nm DOPG particle size (see Figure 5E).
Our results are in agreement with the literature, where
liposomes formulated with negatively charged lipids (PS-based
liposomes) with a size of 85 nm showed the best internalization
Figure 5. A) Size, B) anisotropy, C) zeta potential, D) UHPLC-CAD lipid quantification, and E) RAW264.7 uptake, for the different size liposomes
formulated with DOPA, DOPG, and DOPS. Data are represented as mean SD (n¼ 3).
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rate into different cell lines.[9,77] Ultimately, the formulation char-
acterized by the highest uptake into macrophages contained
22mol% of DOPG, 38mol% of Chol, and 40mol% of DOPC
resulting in a size of 116.2 0.2 nm.
2.6. Primary Mouse BMDM-Targeting Liposomes
Aiming to test the translational potential of our systematic
screening approach, we thus moved to BMDMs, a more physio-
logical cellular model obtained by in vitro differentiation of pri-
mary hematopoietic progenitors isolated from the bone marrow
of mice and often used to model the characteristics of MdMs
found in inflamed tissues. Although RAW264.7 is recognized
widely as a monocyte/macrophage model, significant differences
with BMDMs, such as varying expression levels of a large num-
ber of proteins including important receptors, are reported.[26]
Hence, we aimed to verify if the uptake obtained from the
RAW264.7 cell line was comparable with that achieved by pri-
mary cells. The investigation was conducted using three formu-
lations: 1) pure DOPC liposomes as a negative control, 2) DOPS-
based liposomes as a positive control as PS is one of the most
used membrane-anchored eat-me signals, and 3) DOPG
liposomes, which stood out as the best formulation taken up
by RAW264.7 cells. The PS- or PG-based liposomes were both
formulated with a diameter of 100 nm and each contained
22mol% of NPL and 38mol% of Chol. As evident from the con-
focal images (Figure 6, panel A and B) and confirmed quantita-
tively by flow cytometry (Figure 6, panel C and D), a similar trend
was observed in both types of cells. As with RAW264.7 cells, the
PG-based liposomes also showed the highest uptake by the
BMDMs when compared with either the pure DOPC or the “gold
standard” PS-based liposomes. Therefore, the ability of the PG
candidate to be taken up by BMDMs in a similar manner as
by RAW264.7 cells was confirmed, thus validating the robustness
and versatility of our iterative procedure in the optimization of
formulations for cell targeting. As in the case of RAW264.7 cells,
the phagocytic affinity of BMDMs for PG-based liposomes could
be explained by an SR-independent pathway for PG-containing
particles. Whereas PS liposomes are mainly dependent on
SRs function for uptake, PG liposomes could be engulfed via
at least one additional mechanism of uptake[66] and very likely
the observed uptake is mediated by several receptors/molecules
including SRs. Moreover, it has been shown that a higher serum
protein-binding capacity of DOPG liposomes is correlated with
Figure 6. Liposomes uptake after 3 h of incubation followed by confocal microscopy on A) RAW264.7 cells (scale bar: 20 μm) and on B) BMDM (scale bar:
20 μm) and uptake by C) RAW264.7 cells and D) BMDM measured by flow cytometry. Data are represented as mean SD (n¼ 3). Differences between
groups were calculated by an ordinary one-way ANOVA combined with Sidak’s multiple comparisons test after conducting the normality test
(Shapiro–Wilk). Results are considered statistically significant if p≤ 0.05 (*), p≤ 0.01 (**), p≤ 0.001 (***), and p≤ 0.0001 (****).
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their uptake efficiency by HeLa cells. By changing the lipid com-
position and specifically, using PG liposomes, either the amount
or the identity of the proteins absorbed on vesicles surface can
vary dramatically. In a previous study, the inclusion of DOPG
lipid allowed for specific interactions between the lipid head
group and the serum proteins which in turn led to a higher
uptake.[78] Similar results have been obtained on bone marrow
dendritic cells: PG-containing liposomes have been reported to
mediate a superior antigen-specific response compared with
PS liposomes or cationic liposomes. It was found that PG lipo-
somes attract complement proteins, especially C1q, from the cir-
culation more efficiently than PS liposomes.[66] However, further
investigations are needed to elucidate the specific receptor
involved in the uptake and its mechanism.
3. Conclusion
In the past decades, a manifold of different particle modifications
to target macrophages has been proposed. Regrettably, it is still
not well understood as to how each of these variables affects for-
mulation performance. Inconsistent experimental conditions
and missing controls in several studies from the literature (vide
supra) lead to highly contradictory results. In this study, we have
demonstrated the power of the DoE strategy for the development
of liposomes and its ability to minimize the aforementioned dis-
advantages through a systematic, iterative screening. An extreme
vertices design was used to determine the optimal combination
of various lipids to deliver a desired response using a minimum
number of experiments. Our DoE-led comprehensive particle
characterization laid the foundation for the development of
the most suited formulation (100 nm size and composed of
22mol% of DOPG, 38mol% of Chol, and 40mol% of DOPC)
for enhanced macrophage uptake. The results suggest that,
although low rigidity of the phospholipid bilayer is beneficial
for interaction with macrophages, it is seemingly not the only
parameter to be taken into account, as other variables, such as
Chol content, different NPLs, their concentration, and particle
size, also critically affected the uptake. As a first step to test
the translational potential of our systematic screening approach,
the best candidate identified for the RAW264.7 cell line was con-
firmed with BMDM primary cells. For the first time, to our
knowledge, our systematic approach allowed for the production
of a suitable fluorescent liposome formulation efficiently taken
up by both immortalized and primary macrophages. This study
has set the stage for further in vivo studies to confirm the uptake
of optimized liposomes by macrophages in different tissues, with
the potential goal to modulate the function of this critical cell type
in a wide range of inflammatory and immune pathologies.
4. Experimental Section
Materials and Methods: The phospholipids 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-
2-oleoyl-glycero-3-phosphocholine (POPC), 1,2-di-(9Z-octadecenoyl)-
sn-glycero-3-phospho-(1 0-rac-glycerol) (sodium salt) (DOPG),
1,2-distearoyl-sn-glycero-3-phospho-(1 0-rac-glycerol) sodium salt (DSPG),
and 1,2-dioleoyl-sn-glycero-3-phosphate sodium salt (DOPA) were kindly
gifted by Lipoid (Ludwigshafen, Germany). 1,2-dipalmitoyl-sn-glycero-3-
phospho((ethyl-1 0,2 0,3 0-triazole)triethyleneglycolmannose) (ammonium
salt) (DPPA-PEG2-mannose), 1,2-dioctadecanoyl-sn-glycero-3-phosphate
(sodium salt) (1,2-dioctadecanoyl-sn-glycero-3-phosphate (sodium salt)
(DSPA), 1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine (sodium salt)
(DPPS), 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-L-
serine (sodium salt) (POPS), L-alpha-PS (brain, porcine) (sodium salt)
(Brain PS), and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt)
(DOPS) were purchased from Avanti Polar Lipids (Alabaster, USA).
3,3’-dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1 0-dioctadecyl-
3,3,3 0,3 0-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt
(DiD) were bought from Thermo Fisher Scientific (Waltham, MA,
USA). RAW264.7 cell line (Merck, ECACC 91062702, ATCC-TIB-71, Mus
musculus-derived macrophages), HEK293 cell line (Merck, ECACC
85120602, human embryo kidney), penicillin/streptomycin solution (peni-
cillin: 10 000 UmL1, streptomycin: 10 000 μgmL1), L-glutamine
(200mM), fetal bovine serum (FBS), cholesterol (Chol), 1,6-diphenyl-
1,3,5-hexatriene (DPH), and palmitic acid were obtained from Merck
(Darmstadt, Germany). Trifluoracetic acid (TFA), ethylenediaminetetra-
acetic acid sodium salt (EDTA), Dulbecco’s Modified EagleMedium—high
glucose (DMEM), Dulbecco’s phosphate buffed saline (with and without
calcium and magnesium) (DPBS), ROTI Histofix 4%, 4 0,6-diamidino-2-
phenylindole dihydrochloride (DAPI), and propidium iodide were obtained
from Carl Roth (Karlsruhe, Germany). All organic solvents (chloroform,
methanol, acetonitrile, ethanol, and tetrahydrofuran [THF]) were obtained
from Fisher Scientific (Schwerte, Germany).
Design of Experiment: The DoE approach allows to simultaneously
investigate the effect of input variables and observe how these affect prod-
uct quality. Mixture design was selected to optimize the proportions of
lipids in liposome formulation to maximize a desired response using a
minimum number of experiments. In this specific design, the response
(i.e., the macrophages uptake expressed as geometric mean fluorescence
intensity values from flow cytometry experiments) is a function of the pro-
portions of the different lipid components in the mixture that must add up
to one.[79] As it was not desirable to have all constituents of the mixture
varied in the ratio of zero to one, an extreme vertices design with lower-
and upper-bound constraints on the components was used. The con-
straints placed on the individual factors describe an irregular hyperpoly-
hedron:[80] the vertices and centroids of this figure describe the 11
points of the experiment (see Figure S1, Supporting Information) used
to estimate the response in the surface plot, where ranges of different geo-
metric mean fluorescence intensity values obtained from flow cytometry
experiments are divided in colored contour bands. Four independent DoE,
in which neutral lipids (DOPC, POPC, DPPC, and DOPCþDSPC 50/50
mixture; with lower and upper bounds of 40 and 100 molar percentage,
respectively) were formulated together with negatively charged lipids
(DOPS, POPS, DPPS, Brain PS, respectively; with lower and upper bounds
of 0 and 30 molar percentage, respectively) and cholesterol (Chol; with
lower and upper bounds of 0 and 40 molar percentage, respectively), were
conducted (see Table S1, Supporting Information). It is worth noting that
each formulation contained a pair of neutral and negatively charged lipids
having the same chain length and degree of unsaturation, resulting in a
negligible hydrophobic mismatch, a phenomenon known to perturb the
bilayer stability and membrane fluidity. Namely, DOPC was coformulated
with DOPS, POPC, with POPS and the mixture DOPC/DSPC 50/50 with
Brain PS. Each DoE consisted of 11 different liposome formulations con-
ducted in triplicate. The model was fitted by a special cubic equation for
three components using a statistical software (Minitab 18.1, Pennsylvania.
USA). All the analyses together with a detailed description of the DoE are
reported in Supporting Information (Figure S1 and S2; Tables S1–S13,
Supporting Information).
Liposome Preparation: Liposomes containing the different lipid
compositions were prepared by means of the film hydration method.
Appropriate amounts of lipid stock solutions in chloroform and 0.1mol%
DiD or DiO were transferred into amber glass vials and the organic solvent
was evaporated under a nitrogen stream until it dried. Both lipid dyes were
routinely used for liposome research and they were reported to be non-
exchangeable.[81] Subsequently, solvent traces were removed by vacuum
overnight. After hydration with DPBS (without calcium and magnesium,
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to prevent aggregation of liposomes), the liposomal formulations was
extruded five times through a 100 nm polycarbonate membrane
(Whatman Nucleopore, Maidstone, UK) at room temperature (RT) for
unsaturated lipid chains or above phase transition temperature for satu-
rated lipid chains using a LIPEX extruder (Evonik, Canada). After liposome
preparation, the lipid content of the different formulations was analyzed by
a UHPLC-CAD-based approach (see Supporting Information) using a
method previously developed in our group.[82]
Size Evaluation and Zeta Potential: The hydrodynamic diameter and the
polydispersity index (PDI) of the liposomes were determined by a Litesizer
500 (Anton Paar, Graz, Austria) equipped with a 175 backscatter angle
detector and a semiconductor laser with λ¼ 658 nm. Briefly, the liposome
formulations were diluted to a concentration of 100 μM, and 1mL of the
diluted dispersion was transferred into disposable semimicro cuvettes.
After equilibrating the sample at 25 C, measurement was carried out
(6 runs 30 s for each sample). The zeta potential was determined by
means of continuously monitored phase analysis light scattering
(cmPALS) in an Omega cuvette (Anton Paar, Graz, Austria), where a
refractive index of 1.33 and a viscosity of 0.89 mPa/s were set for the sol-
vent. The intensity size distribution of the liposome was unimodal; there-
fore, the autocorrelation function was analyzed according to the cumulant
method by the Kalliope™-software (Anton Paar).
Fluorescence Anisotropy: DPH was dissolved in THF to a concentration
of 10 μgmL1 and stored at20 C, protected from light. For the analysis,
1 mL of liposome formulation (100 μM) was then mixed with DPH stock
solution in a molar ratio of DPH: lipid (1:300). After 30 min incubation
time at 37 C and 300 rpm, 200 μL was transferred into a black 96-well
plate (BRAND, Wertheim, Germany). After two additional shaking steps
(orbital, 5 s), fluorescent anisotropy was determined by means of an
Infinite 200 Pro F-Plex plate reader (Tecan, Männedorf, Switzerland)
equipped with λex¼ 360 35 nm and λem¼ 430 20 nm broad-pass fil-
ters at 37 C and calculated using Equation (1).
r ¼ GIk  I⊥
GIk þ 2I⊥
(1)
where Ik and I⊥ are the fluorescence intensities measured parallel and per-
pendicular to the vertically polarized exciting beam, and G (1.013) is an
intrinsic parameter of the spectrometer.
Cell Culture: Semiadherent mousemonocyte macrophages (RAW264.7)
were cultured at 37 ºC in a humidified atmosphere containing 5% CO2 in
DMEM (4.5 g L1 glucose and phenol red) supplemented with 1% v/v
penicillin/streptomycin mixture, 1% v/v L-glutamine (200 nM), and
10% v/v FBS. After reaching 70–80% of confluence, the cells were
detached by a cell scraper and used for further subcultivation.
Adherent human embryonic kidney cells (HEK293) were cultured at
37 ºC in a humidified atmosphere containing 5% CO2 in DMEM
(4.5 g L1 glucose and phenol red) supplemented with 1% v/v penicil-
lin/streptomycin mixture, 1% v/v of L-glutamine (200 nM), and 2% v/v
FBS. After reaching 90% confluence, the cells were enzymatically detached
and used for further subcultivation. Cells were regularly checked for the
absence of mycoplasma.
BMDMs were isolated from the tibia, femur, and pelvic bones of 6–12-
week-old C57BL/6 J male mice according to a previously established pro-
tocol.[27] Briefly, the marrow was flushed from the hind leg bones using
BMDM media containing RPMIþGlutamine supplemented with 10%
heat-inactivated FBS (FBS Gold, Gibco, Paisley, UK) and 100 IUmL1 pen-
icillin/streptomycin (P/S, Gibco, Paisley, UK). After thorough resuspen-
sion, the cells were filtered through a 100 μm pore mesh and
incubated with 1 ml ammonium–chloride–potassium (ACK) Lysis Buffer
(Gibco, Grand Island, NY, USA) to deplete erythrocytes. After washing,
the cells were resuspended in BMDM media supplemented with
5 ngmL1 recombinant mouse macrophage colony stimulating factor
(mCSF, R&D Biosystems, Minneapolis, USA, 416-ML-500) and plated
in nontreated cell culture Petri dishes (100mm, Greiner Bio-One, St
Gallen, Switzerland). A total of 20 106 hematopoietic stem cells per dish
were cultured for 7 days at 37 C, 5% CO2, with media exchange at culture
day 4. At culture day 7, 1.5–3 106 cells per Petri dish were obtained.
Flow Cytometry: The uptake of different liposomal formulations was
tested using three different cell types: RAW264.7, HEK293, and primary
BMDMs. Briefly, 0.4 106 cells/well (RAW264.7) and 0.2 106 cells/well
(HEK293) were seeded into 12-well plates (SPL Life Science) with 1 mL
full-growth medium and cultured for 18 h at 37 C, 5% CO2, to 90% con-
fluence, whereas primary BMDMs were used at culture day 7 post-
isolation, at a confluence of 2 106 cells/100mm Petri dish. Prior to
incubation with warm DPBS (with calcium and magnesium, to prevent
detachment of the cells). Liposome stock dispersions were diluted in
the following cell culture media at a final concentration of 100 μM: for
RAW264.7 and HEK293, we used phenol red-free DMEM containing
4.5 g L1 glucose supplemented with 1% v/v penicillin/streptomycin mix-
ture, 1% v/v of L-glutamine (200 nM), and 2% v/v FBS, whereas for pri-
mary BMDMs, RPMI media supplemented with 10% FBS, 100 IUmL1
P/S, and 5 ngmL1 mCSF were used. All three cell types were then incu-
bated for 180min at 37 C (100 rpm) with liposomal formulations. After
incubation, the supernatant was removed, and cells were washed three
times with ice-cold “FACS buffer” (DPBS without calcium and magnesium
supplemented with 0.02 % w/v EDTA and 2% v/v FBS). Subsequently,
RAW264.7 and HEK293 cells were detached with a cell scraper and pipet-
ted into 1.5 mL reaction tubes. BMDM detachment was achieved by incu-
bation of cells with 0.5% trypsin (Gibco, Paisley, UK, 25300-054) for 10min
at 37 C, following which the enzyme was inactivated with BMDM media.
After two additional washing steps, RAW264.7 and HEK293 cells were dis-
persed in 600 μL FACS buffer and transferred to the flow cytometer.
BMDMs were additionally incubated on ice for 15min with anti-CD16/
32 (produced in house) to block the FC receptors and then incubated
with the following reagents diluted in FACS buffer for 30 min at 4 C in
light-protected conditions: PE-Cy7 conjugated anti-mouse CD11b (clone
M1/70, Biolegend, San Diego, CA, USA, catalogue number 101216),
Brilliant Violet 711 conjugated anti-mouse CD45 (clone 30-F11, Biolegend,
San Diego, CA, USA, catalogue number 103146), and cell viability dye
eFluor 506 (Invitrogen, Rockford, IL, USA, catalogue number 65-0866-14).
RAW264.7 and HEK293 cells were stained for 10min with 50 μgmL1
propidium iodide diluted in ultrapure water for viability assessment.
After antibody washout with 1DPBS and prior to analysis, the cell dis-
persions were filtered through a 50 μm mesh (Hartenstein, Würzburg,
Germany) to exclude clusters of cells. An LSR II SORP (BD Biosciences,
Allschwill, Switzerland) reader was used to acquire the data for RAW264.7
and HEK293 cells, and an Attune NxT cytometer (Thermo Fisher Scientific,
Rochester, NY, USA) was used for BMDM analysis. A minimum of
10 000 living cells per sample was recorded. The fluorescence intensity of
the dye bound to the cell surface and/or internalized by the cells was
assessed by means of a gating strategy shown in Supporting Information
(Figure S3 and S4, Supporting Information). FlowJo software (version 10,
Ashland, OR; USA) was used for data analysis and the geometric mean
of the fluorescence intensity (GeoMean) measured by flow cytometry
was chosen as output for the uptake of the different particles. GeoMean
was proportional to the liposome/dye uptake where all the produced par-
ticles had the same fluorescence intensity and the same cell viability after
incubation (See Figure S5 and S6 respectively, Supporting Information).
Confocal Microscopy: To observe the intracellular distribution and the
fluorescence intensity of liposome formulations, we used confocal micros-
copy. For this purpose, 0.2 106 cells/well (RAW264.7) were seeded into
12-well plates (SPL Life Science) equipped with 1 glass coverslip per well.
After 18 h, the cell culture medium was discarded, and wells were washed
two times with DPBS (37 C). In parallel, BMDMs were isolated and cul-
tured on glass slides in 12-well plates (SPL Life Science) in BMDM media
supplemented with 5 ngmL1 mCSF at a density of 2.5 106 cells per
well. Liposome stock dispersions with DiD were diluted in phenol red-free
DMEM (for RAW264.7 cells)/BMDM media containing mCSF (for
BMDMs) as described above and carefully pipetted onto the cells. Cells
were then incubated with the liposomes for 180min at 37 C. After incu-
bation, the supernatant was removed, and cells were washed three times
with DPBS. Cells were then fixed with 1% paraformaldehyde (PFA, Merk
Darmstadt, Germany) for 10min at RT in light-protected conditions. After
fixation and two washing steps with DPBS, nuclei staining was achieved by
incubation of cells with DAPI (200 ngmL1, AppliChem, Darmstadt,
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Germany) diluted in 1DPBS. After additional two washing steps, cells
were mounted with Mowiol 4-88 (Sigma-Aldrich, St Louis, MO, USA) and
covered with glass slides. Imaging was conducted with a Zeiss LSM 800
(Carl Zeiss AG, Jena, Germany) confocal microscope, using a 40/1.3 oil
objective. For each sample, three pictures were acquired from three dif-
ferent fields of view.
Statistical Analysis: Results were expressed as mean S.D. (n¼ 3).
Differences between groups were calculated by an ordinary one-way
ANOVA combined with Sidak’s multiple comparisons test after conduct-
ing normality test (Shapiro-Wilk). Results were considered statistically sig-
nificant if p≤ 0.05 (*), p≤ 0.01 (**), p≤ 0.001 (***), and p≤ 0.0001
(****).
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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